Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 123 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2014', provides an overview of the Squamous Non-Small Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Squamous Non-Small Cell Lung Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Overview 9
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Comparative Analysis 10
Squamous Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 11
Squamous Non-Small Cell Lung Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Squamous Non-Small Cell Lung Cancer - Products under Development by Companies 15
Squamous Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 16
Bristol-Myers Squibb Company 16
Johnson & Johnson 17
Boehringer Ingelheim GmbH 18
AstraZeneca PLC 19
Eli Lilly and Company 20
Novartis AG 21
Eisai Co., Ltd. 22
Ono Pharmaceutical Co., Ltd. 23
Vertex Pharmaceuticals Incorporated 24
Celgene Corporation 25
Bayer AG 26
Oncogenex Pharmaceuticals, Inc. 27
Ascenta Therapeutics, Inc. 28
Five Prime Therapeutics, Inc. 29
Advenchen Laboratories, LLC 30
AbbVie Inc. 31
Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ipilimumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
necitumumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
paclitaxel - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
veliparib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
nivolumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
lenvatinib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
apatorsen - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
buparlisib hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LY-2606368 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
lucitanib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
VX-970 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
nintedanib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
JNJ-42756493 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
FP-1039 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AT-406 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
AZD-8186 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
BAY-1163877 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Squamous Non-Small Cell Lung Cancer - Recent Pipeline Updates 82
Squamous Non-Small Cell Lung Cancer - Dormant Projects 113
Squamous Non-Small Cell Lung Cancer - Discontinued Products 114
Squamous Non-Small Cell Lung Cancer - Product Development Milestones 115
Featured News & Press Releases 115
Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment 115
May 15, 2014: English Court Rules Against Lilly in Alimta Vitamin Dosage Regimen Patent Lawsuit 115
May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting 116
Jan 16, 2014: Biothera Research Shows Potential for Treating Imprime PGG Biomarker-Negative Cancer Patients 116
Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint 117
Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 118
May 23, 2013: OncoGenex Pharma Announces Plans For Initiation Of Cedar Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer 118
May 15, 2013: Boehringer Ingelheim To Present Six Abstracts For Nintedanib At ASCO 2013 119
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 120
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 121
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Tables
Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2014 9
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Squamous Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 16
Squamous Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2014 17
Squamous Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 18
Squamous Non-Small Cell Lung Cancer - Pipeline by AstraZeneca PLC, H2 2014 19
Squamous Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2014 20
Squamous Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2014 21
Squamous Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H2 2014 22
Squamous Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 23
Squamous Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 24
Squamous Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H2 2014 25
Squamous Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2014 26
Squamous Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 27
Squamous Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 28
Squamous Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2014 29
Squamous Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 30
Squamous Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Squamous Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H2 2014 82
Squamous Non-Small Cell Lung Cancer - Dormant Projects, H2 2014 113
Squamous Non-Small Cell Lung Cancer - Discontinued Products, H2 2014 114